Verona Pharma plc
("Verona Pharma" or the "Company")
Result of AGM
11 June 2015, Cardiff –
Verona Pharma plc (AIM: VRP), the drug development company focused
on first-in-class medicines to treat respiratory diseases,
announces that all resolutions proposed at the Annual General
Meeting (AGM) held today were duly passed.
A presentation on Verona Pharma made by its Chief Executive
Officer, Dr. Jan-Anders Karlsson,
will be available to view on the Company’s website
http://www.veronapharma.com/.
-Ends-
For further information please
contact:
| Verona Pharma plc |
Tel: +44 (0) 20 7863
3300 |
| Jan-Anders Karlsson, CEO |
|
|
|
| N+1 Singer |
Tel: +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer |
|
|
|
| FTI Consulting |
Tel: +44 (0)20 3727 1000 |
| Julia Phillips / Simon Conway |
|
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical
company focused on the development of innovative prescription
medicines to treat respiratory diseases with significant unmet
medical needs, such as chronic obstructive pulmonary disease
(COPD), asthma and cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in Phase 2 trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential
to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for
COPD and asthma maintenance therapy. The Company is also
exploring the potential of the drug in different diseases, such as
cystic fibrosis, where it is in pre-clinical testing and has
recently received a Venture and Innovation Award from the UK Cystic
Fibrosis Trust.